The NLRP3 inflammasome contributes to pathogenic inflammation in a broad range of diseases, making it a highly relevant drug target. Two studies published in this issue found an inhibitor of NLRP3 inflammasome activation to directly bind NLRP3 within its central NACHT domain, interfering with ATP hydrolysis and structural changes critical for NLRP3 oligomerization and subsequent inflammasome formation.
This is a preview of subscription content, log in via an institution to check access.
References
Martinon, F., Mayor, A. & Tschopp, J. Annu. Rev. Immunol. 27, 229–265 (2009).
Coll, R. C. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0277-7 (2019).
Tapia-Abellán, A. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0278-6 (2019).
Duncan, J. A. et al. Proc. Natl. Acad. Sci. USA 104, 8041–8046 (2007).
Brydges, S. D. et al. Immunity 30, 875–887 (2009).
Shao, B. Z., Xu, Z. Q., Han, B. Z., Su, D. F. & Liu, C. Front Pharmacol. 6, 262 (2015).
Perregaux, D. G. et al. J. Pharmacol. Exp. Ther. 299, 187–197 (2001).
Coll, R. C. et al. Nat. Med. 21, 248–255 (2015).
van Hout, G. P. et al. Eur. Heart J. 38, 828–836 (2017).
Jiang, H. et al. J. Exp. Med. 214, 3219–3238 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Gorka, O., Neuwirt, E. & Groß, O. Walking over the inflammasome. Nat Chem Biol 15, 552–553 (2019). https://doi.org/10.1038/s41589-019-0292-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-019-0292-8
- Springer Nature America, Inc.